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nteBACKGROUND Pheochromocytoma is associated with catecholamine-induced cardiac toxicity, but the extent and
nature of cardiac involvement in clinical cohorts is not well-characterized.
OBJECTIVES This study characterized the cardiac phenotype in patients with pheochromocytoma using cardiac
magnetic resonance (CMR).
METHODS A total of 125 subjects were studied, including patients with newly diagnosed pheochromocytoma (n ¼ 29),
patients with previously surgically cured pheochromocytoma (n ¼ 31), healthy control subjects (n ¼ 51), and hypertensive
control subjects (HTN) (n ¼ 14), using CMR (1.5-T) cine, strain imaging by myocardial tagging, late gadolinium
enhancement, and native T1 mapping (Shortened Modiﬁed Look-Locker Inversion recovery [ShMOLLI]).
RESULTS Patients who were newly diagnosed with pheochromocytoma, compared with healthy and HTN control
subjects, had impaired left ventricular (LV) ejection fraction (<56% in 38% of patients), peak systolic circumferential
strain (p < 0.05), and diastolic strain rate (p < 0.05). They had higher myocardial T1 (974  25 ms, as compared with
954 16ms in healthy and 958 23ms in HTN subjects; p<0.05), areas ofmyocarditis (median 22% LVwith T1>990ms,
as compared with 1% in healthy and 2% in HTN subjects; p < 0.05), and focal ﬁbrosis (59% had nonischemic late
gadolinium enhancement, as compared with 14% in HTN subjects). Post-operatively, impaired LV ejection fraction
typically normalized, but systolic and diastolic strain impairment persisted. Focal ﬁbrosis (median 5% LV) and T1
abnormalities (median 12% LV) remained, the latter of which may suggest some diffuse ﬁbrosis. Previously cured patients
demonstrated abnormal diastolic strain rate (p < 0.001), myocardial T1 (median 12% LV), and small areas of focal ﬁbrosis
(median 1% LV). LV mass index was increased in HTN compared with healthy control subjects (p < 0.05), but not in the
2 pheochromocytoma groups.
CONCLUSIONS This ﬁrst systematic CMR study characterizing the cardiac phenotype in pheochromocytoma showed
that cardiac involvement was frequent and, for some variables, persisted after curative surgery. These effects surpass
those of hypertensive heart disease alone, supporting a direct role of catecholamine toxicity that may produce subtle but
long-lasting myocardial alterations. (J Am Coll Cardiol 2016;67:2364–74) © 2016 by the American College of Cardiology
Foundation.m the aOxford Centre for Clinical Magnetic Resonance Research, Division of Cardiovascular Medicine, Radcliffe Department of
dicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom; bDepartment of Endocrinology, Oxford Centre
Diabetes, Endocrinology & Metabolism (OCDEM), Churchill Hospital, University of Oxford, Oxford, United Kingdom;
epartment of Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; dDepartment of Endo-
nology, Barts and the London School of Medicine, Queen Mary University of London, London, United Kingdom; eInstitute of
nt.onlinejacc.org/ on 05/17/2016
AB BR E V I A T I O N S
AND ACRONYM S
CMR = cardiac magnetic
resonance
IQR = interquartile range
LGE = late gadolinium
enhancement
LV = left ventricular
LVEF = left ventricular
ejection fraction
LVH = left ventricular
rtrophy
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DownloaP heochromocytomas are rare neuroendocrinecatecholamine-secreting tumors originatingfrom chromafﬁn cells within the adrenal me-
dulla or extra-adrenal paraganglia, with an annual
incidence of approximately 0.8/100,000 person-years
(1–3). Catecholamine-induced cardiovascular compli-
cations carry a high risk of morbidity and mortality
and may include hypertensive crisis, stroke, aortic
dissection, myocardial infarction (MI), arrhythmia,
and heart failure (4–6). Various cardiac pathologies
have been described, including cardiac hypertrophy,
stress-induced cardiomyopathy, myocarditis, systolic
and diastolic dysfunction, and dilated cardiomyopa-
thy (4–7). Further, catecholamines have been shown
to inﬂuence the extracellular matrix with collagen
deposition and subsequent ﬁbrosis in the myocardium
(6,8). These changes are beyond hypertensive effects
alone, mediated by catecholamines via stimulation of
myocardial alpha- and beta-adrenoceptors (9,10) or
as a direct toxic effect on myocytes (11–14).SEE PAGE 2375Due to the condition’s rarity, studies of cardiac
pathology in pheochromocytoma are mostly limited
to case reports or series (1), and the true underlying
phenotype is not well-described. Few clinical studies
have fully characterized cardiac involvement in pa-
tients with pheochromocytoma, with most employing
electrocardiography or echocardiography, which are
limited by the lack of myocardial tissue character-
ization; thus, the true extent of myocardial involve-
ment is unknown.
Cardiac magnetic resonance (CMR) is ideal for
examining the heart in pheochromocytoma due to its
multiparametric capabilities for myocardial tissue
characterization. It provides an accurate and repro-
ducible method for left ventricular (LV) anatomy, car-
diac indexes, and regional and global function. Tagged
CMR measures myocardial strain parameters and
detects subtle systolic and diastolic dysfunction.
Late gadolinium enhancement (LGE) imaging allowsMetabolism and Systems Research, University of Birmingham, Birmingham, U
and Metabolism, Birmingham Health Partners, Birmingham, United Kingd
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Fund Scholarship. Drs. Piechnik and Robson have 2 pending U.S. patents: 6
locker inversion recovery (sh-molli) cardiac gated mapping of T1, all rights
61/689,067, color map design method for immediate assessment of the dev
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Manuscript received October 14, 2015; revised manuscript received February
ded From: http://content.onlinejacc.org/ on 05/17/2016visualization of the type and distribution of
ischemic versus nonischemic type focal
ﬁbrosis. There have been 2 case reports
demonstrating the utility of CMR in detecting
catecholamine myocarditis in pheochromo-
cytoma (15,16). Most recently, CMR T1 map-
ping, on the basis of measurement of the
magnetic property myocardial T1 (or the pro-
ton spin-lattice relaxation) times on a pixel-
by-pixel basis, has proven to be a robust tool
sensitive to myocardial inﬂammation
and diffuse ﬁbrosis in a variety of cardiac
conditions (17,18). Thus, CMR provides a comprehen-
sive means to characterize the cardiac phenotype in
pheochromocytoma.
We performed the ﬁrst prospective, systematic
study to determine the extent of cardiac involvement
in patients with pheochromocytoma using CMR. We
hypothesized that cardiac involvement would be
common and detectable using advanced tissue char-
acterization techniques.
METHODS
This was a prospective study including 125 subjects:
60 patients with a new (n ¼ 29) or previous (n ¼ 31)
diagnosis of pheochromocytoma, without known
cardiovascular disease; 51 healthy control subjects
(age- and sex-matched), and 14 patients with essen-
tial hypertension. Patients with pheochromocytoma
were recruited from 3 hospitals in the United
Kingdom: 1) Department of Endocrinology, Oxford
Centre for Diabetes, Endocrinology and Metabolism,
Churchill Hospital, Oxford; 2) Department of Endo-
crinology, Barts and the London School of Medicine,
Queen Mary University of London; and 3) Department
of Endocrinology, Queen Elizabeth Hospital, Univer-
sity Hospitals Birmingham NHS Foundation Trust,
Birmingham. Patients underwent CMR at the Uni-
versity of Oxford Centre for Clinical Magnetic Reso-
nance Research, John Radcliffe Hospital between
hypenited Kingdom; fCentre for Endocrinology, Diabetes
om; and the gSiemens Healthcare GmbH, Erlangen,
National Institute for Health Research (NIHR) Oxford
tion Trust and the University of Oxford. Dr. Ferreira
Fellowship and the University of Oxford Clarendon
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iation from established normal population statistics
ployee of Siemens Healthcare GmbH. Dr. Neubauer
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Downloaded From: http://coAugust 2009 and December 2014. Patients had a
diagnosis of pheochromocytoma, as assessed by
consultant endocrinologists, on the basis of
biochemical testing (including urinary catechol-
amines and plasma and/or urinary metanephrines),
and conﬁrmed with cross-sectional imaging and
subsequent positive histopathology (more clinical
and tumor details available in the Online Appendix).
Newly diagnosed patients were assessed pre-
operatively after initiation of alpha-blockade with or
without beta-blockade. Of these, 18 patients were
available for repeat post-operative CMR scanning;
other patients were not available due to serious
illness (noncardiac or endocrine causes; n ¼ 2), per-
manent pacemaker insertion precluding CMR (n ¼ 1),
living long distances away (n ¼ 3), choosing not to
participate (n ¼ 4), or being lost to follow-up (n ¼ 1).
Additionally, we invited 31 previously diagnosed pa-
tients who were surgically cured and were without
evidence of ongoing disease.
Exclusion criteria included inability to tolerate
CMR, contraindications to CMR, known signiﬁcant
cardiac disease (previous MI, previous myocarditis,
heart failure, signiﬁcant valvular disease, or other
chronic cardiac condition), and signiﬁcant renal
impairment (estimated glomerular ﬁltration
rate <30 ml/min).
Healthy volunteers (age- and sex-matched) with no
cardiac history or risk factors, who were not on car-
diovascular medications, and who had a normal elec-
trocardiogram acted as control subjects. Patients with
a diagnosis of essential hypertension (Online
Appendix) without other signiﬁcant comorbidities
who had been on antihypertensive treatment for at
least 3months andwerewithout severe left ventricular
hypertrophy (LVH) acted as another control group.
Hypertensive control subjects without severe LVH
were speciﬁcally chosen to more closely match the
morphological LV phenotype of the patients with
pheochromocytoma. Ethical approval was granted for
all study procedures; all subjects gave written
informed consent.
CMR was performed on a single 1.5-T magnetic
resonance system (Magnetom Avanto, Siemens
Healthcare, Erlangen, Germany) using established
CMR techniques and a 32-channel phased-array coil, as
previously published (19). These included cine, strain
imaging by myocardial tagging, LGE, and native T1
mapping (Shortened Modiﬁed Look-Locker Inversion
recovery) (20). For further details, see the Online
Appendix.
STATISTICAL ANALYSIS. Normality of data was
tested using the Kolmogorov-Smirnov test. Normally
distributed data are presented as mean  SD;ntent.onlinejacc.org/ on 05/17/2016nonparametric data as median with interquartile
ranges (IQRs). Paired samples were assessed by
paired Student t test or the Wilcoxon signed rank test
for nonparametric data. Unpaired samples were
assessed by the unpaired 2-tailed Student t test or the
Mann-Whitney U test for nonparametric data. Any
segmental analysis was averaged on a per-subject
basis before any interindividual and group compari-
sons to control for clustering of segments within each
subject. To determine the presence of signiﬁcant
differences in subject groups when using multiple
CMR methodologies, analysis of variance was per-
formed with Bonferroni-corrected post hoc compari-
sons for parametric data; for nonparametric data, the
Kruskal-Wallis 1-way analysis of variance was per-
formed with post-hoc pairwise comparisons. To
compare the extent of myocardial injury measured by
2 different CMR tissue characterization sequences
(LGE and T1 mapping) within the same patient sub-
group, the Wilcoxon test was used for nonparametric
data with post hoc comparisons. The Fisher exact test
was used for comparison of categorical data. All sta-
tistical tests were 2-tailed, with p values <0.05
considered statistically signiﬁcant. Statistical ana-
lyses were performed using MedCalc (version 11.5.1.0,
MedCalc Software, Mariakerke, Belgium).
RESULTS
Baseline characteristics of patients with pheochro-
mocytoma compared with matched control subjects
are presented in Table 1.
Newly diagnosed patients underwent CMR soon
after diagnosis and before surgery (median 2 months;
IQR: 1 to 4 months). Most (97%) were in sinus rhythm,
whereas 1 (3%) was in atrial ﬁbrillation and another
(3%) had frequent ectopy at the time of scan. Follow-
up CMR was performed at a mean of 12  5 months.
Previously diagnosed and cured patients under-
went CMR examination at a median of 51 months
(IQR: 27 to 83 months) from the date of surgical
resection of their pheochromocytoma. All were in si-
nus rhythm at the time of scan. In this group, only
those who had abnormal CMR ﬁndings (7 of 31, 23%)
were invited for a repeat CMR examination for follow-
up (mean 25  10 months; n ¼ 5).
CARDIAC FINDINGS USING CMR CHARACTERIZATION.
The CMR ﬁndings (Central Illustration, Figure 1) for
each group of patients were compared with both
healthy control subjects (age- and sex-matched) and
hypertensive control subjects (Table 1).
Newly diagnosed patients had a lower mean left
ventricular ejection fraction (LVEF) compared with
both healthy and hypertensive control subjects
TABLE 1 Clinical and CMR Characteristics
New
Pheochromocytoma
Dx Patients
(n ¼ 29)
Matched
Control Subjects
(n ¼ 29)
Previous
Pheochromocytoma
Dx Patients
(n ¼ 31)
Matched
Control Subjects
(n ¼ 31)
HTN Control
Subjects
(n ¼ 14)
Clinical characteristics
Age, yrs 50  14 50  13 52  14 50  12 55  7
Female 15 (52) 15 (52) 17 (55) 17 (55) 5 (36)
Pre-existing hypertension 5 (17) 0 (0) 3 (10) 0 (0) 14 (100)
Pre-existing diabetes mellitus 5 (17) 0 (0) 3 (10) 0 (0) 0 (0)
Smoking 17 (59) 0 (0) 19 (61) 0 (0) 0 (0)
Time from diagnosis and CMR, months 2 (1–4) N/A 51 (27–83) N/A N/A
On alpha-blockers at time of CMR scan 29 (100) 0 (0) 5 (16) 0 (0) 0 (0)
On beta-blockers at time of CMR scan 21 (72) 0 (0) 2 (6) 0 (0) 1 (7)
Other antihypertensive agents at time of CMR scan
Angiotensin-converting enzyme inhibitor 8 (28) 0 (0) 0 (0) 0 (0) 7 (50)
Angiotensin II receptor blocker 1 (3) 0 (0) 1 (3) 0 (0) 6 (43)
Dihydropyridine calcium-channel blocker 0 (0) 0 (0) 0 (0) 0 (0) 1 (7)
Nondihydropyridine calcium-channel blocker 6 (21) 0 (0) 0 (0) 0 (0) 2 (14)
Thiazide diuretic agent 0 (0) 0 (0) 1 (3) 0 (0) 3 (21)
Thiazide-like diuretic agent 0 (0) 0 (0) 0 (0) 0 (0) 2 (14)
Systolic blood pressure at CMR scan, mm Hg 137  20 130  13 129  19 127  13 135  17
Diastolic blood pressure at CMR scan, mm Hg 83  12 75  8 80  10 75  8 80  11
Heart rate at CMR scan, beats/min 72  14 62  10 67  10 63  9 63  7
Body mass index, kg/m2 22.4  2.5 25.4  3.2 25.9  4.6 24.5  3.6 27.1
CMR characteristics
LV ejection fraction, % 60  9*† 67  4 67  5 67  4 67  4
LV end-diastolic volume indexed to BSA, ml/m2 79  18 73  14 69  12 74  11 78  10
LV end-systolic volume indexed to BSA, ml/m2 33  13*† 24  6 23  6 24  5 26  4
LV mass indexed to BSA, g/m2 56  12‡ 53  11 49  9† 51  9 61  12*
Peak systolic circumferential strain, s1 15.8  2.9*† 18.5  1.4 17.1  2.4* 18.7  1.3 17.3  8.1
Peak diastolic circumferential strain rate, s1 72.8  22.4*† 128.7  29.3 62.8  16.2*† 133.5  25.5 104.7  25.1*
Mean myocardial T1, ms 974  25*† 954  16 959  22 958  19 958  23
Myocardial injury by T1 $990 ms, % 22 (10–37)*† 1 (0–4) 12 (4–19)*† 2 (0–4) 2 (0–5)
Presence of LGE 17 (59)*† 0 (0) 6 (19)* 0 (0) 2 (14)
LV myocardium with LGE >2 SD, % 5 (2–7)* 2 (0–5) 1 (0–3) 0 (0–5) 2 (1–4)
Values are mean  SD, n (%), or median (interquartile range). *Signiﬁcantly different from normal control subjects. †Signiﬁcantly different from HTN control subjects
(p < 0.05). ‡Signiﬁcantly different from patients with a previous diagnosis of pheochromocytoma.
BSA ¼ body surface area; CMR ¼ cardiac magnetic resonance; Dx ¼ diagnosis; HTN ¼ hypertension; LGE ¼ late gadolinium enhancement; LV ¼ left ventricular.
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Downloa(both p < 0.05) (Table 1). On paired analysis, the
average LVEF improved post-operatively in follow-up
(from 60  9% to 63  5%; paired Student t test p <
0.03). Mild global LV dysfunction (LVEF 44% to 56%)
was seen in 38% (11 of 29) of patients, but typically
normalized post-operatively by 1 year (63  5%; range
54% to 70%) in all available for follow-up. At baseline,
newly diagnosed patients had impaired peak systolic
circumferential strain compared with healthy and
hypertensive control subjects (both p < 0.05)
(Figure 2A, Table 1) and diastolic strain rate (both
p < 0.05) (Figure 2B, Table 1). These abnormalities
persisted at follow-up on paired analyses (both
p ¼ NS) (Table 2).
Patients with previously diagnosed and surgically
cured pheochromocytoma had a normal mean LVEFded From: http://content.onlinejacc.org/ on 05/17/2016(67  5%; range 60% to 78%), which was higher than
in newly diagnosed patients (60  9%; p < 0.001), but
no different from healthy or hypertensive control
subjects (67  4% for each respectively; both p ¼ NS).
Interestingly, despite having normal LVEF, these
patients had slightly impaired peak systolic circum-
ferential strain compared with healthy control sub-
jects, but it was not different from hypertensive
control subjects (p ¼ NS) (Figure 2A, Table 1). Previ-
ously diagnosed patients had signiﬁcantly more
impaired diastolic strain rate compared with both
healthy and hypertensive control subjects (all
p < 0.001) (Figure 2B, Table 1). This diastolic func-
tional impairment was similar to that seen in newly
diagnosed patients post-operatively in follow-up
(62.8  16.2 s1 vs. 64.3  18.1 s1; p ¼ NS).
CENTRAL ILLUSTRATION CMR Characterization of Catecholaminergic Cardiac Toxicity in Pheochromocytoma
Ferreira, V.M. et al. J Am Coll Cardiol. 2016;67(20):2364–74.
Cardiac magnetic resonance (CMR) imaging using advanced myocardial tissue characterization techniques was able to detect a wide range of abnormalities related to
catecholamine cardiac toxicity in a live patient cohortwith pheochromocytoma. These include (A) left ventricular dysfunction andpericardial effusion (arrow) (cine imaging,
end-diastolic still frame); (B) subclinical systolic and diastolic dysfunction on strain parameters (tagged CMR; end-systolic still frame); (C) focal and diffuse ﬁbrosis (LGE
imaging demonstrating nonischemic midwall pattern of focal ﬁbrosis) (arrow); and (D) catecholamine myocarditis (T1 map showing elevated global myocardial T1 values
>990 ms). These changes appear to be beyond those seen in hypertensive heart disease alone, and some persisted over time. LGE ¼ late gadolinium enhancement.
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Downloaded From: http://coOf note, LVH was atypical in patients with pheo-
chromocytoma. Newly diagnosed patients had a
normal left ventricular mass index (LVMI) that was not
signiﬁcantly different from healthy or hypertensiventent.onlinejacc.org/ on 05/17/2016control subjects (all p ¼ NS) (Table 1). Compared with
baseline, these patients demonstrated regression of
the LVMI in post-operative follow-up on matched an-
alyses (p ¼ 0.02) back to a level similar to healthy
FIGURE 1 CMR Native T1 Maps and LGE Images
CMR Normal HTN Pheo (new) Pheo (cured)
Colored
T1-map
Threshold
T1-map
LGE
Comparison of colored T1 maps, threshold T1 maps (red indicates T1 >990 ms), and late gadolinium enhancement (LGE) cardiac magnetic
resonance (CMR) images in a normal control subject, a hypertensive control subjects, a patient with newly diagnosed pheochromocytoma
(Pheo), and a patient with previously diagnosed and cured pheochromocytoma.
J A C C V O L . 6 7 , N O . 2 0 , 2 0 1 6 Ferreira et al.
M A Y 2 4 , 2 0 1 6 : 2 3 6 4 – 7 4 Catecholamine Myocarditis in Pheochromocytoma
2369
Downloacontrol subjects (Tables 1 and 2). Previously diagnosed
patients had a normal LVMI compared with healthy
control subjects (p ¼ NS) and a lower LVMI compared
with hypertensive control subjects and newly diag-
nosed patients pre-operatively (both p < 0.05)
(Table 1).
FOCAL MYOCARDIAL FIBROSIS (LGE IMAGING).
There was an increased incidence of focal myocardial
ﬁbrosis, as detected by LGE imaging, in patients both
newly diagnosed and previously diagnosed with
pheochromocytoma. In newly diagnosed patients, a
signiﬁcant proportion (59%; n ¼ 17) demonstrated
scarring, all with a nonischemic pattern (midwall,
subepicardial, or patchy), but these areas were small
(median 5% of LV myocardium; IQR: 2% to 7%) and
did not progress in size or distribution on follow-up.
Interestingly, the frequency of these scars was
signiﬁcantly higher than that seen in hypertensive
control subjects (59% vs. 14%; p < 0.003), but the area
of scarring tended to be small in both groups (median
5% vs. 2%; p ¼ 0.1).
In previously diagnosed patients, a smaller pro-
portion (19%; n ¼ 6) demonstrated scarring compared
with newly diagnosed patients that, again, were all
nonischemic in pattern, were small in area (median
1% of LV myocardium; IQR: 0 to 3%), and did notded From: http://content.onlinejacc.org/ on 05/17/2016progress on follow-up. No patient in either group had
evidence of MI (isolated subendocardial scarring in a
single coronary distribution).
MYOCARDIAL INFLAMMATION AND INVOLVEMENT
(T1 MAPPING). Native T1 mapping revealed signiﬁ-
cant areas of myocardial abnormality beyond those
detected by conventional CMR imaging techniques
(Table 1, Figures 1 and 3).
Newly diagnosed patients had signiﬁcantly higher
average LV myocardial T1 values compared with
healthy and hypertensive control subjects (974 
25 ms vs. 954  16 ms and 958  23 ms, respectively;
both p < 0.05). Further, using the T1 cut-off of 990 ms
previously established for detecting acute myocar-
ditis (19,21), these patients showed signiﬁcantly
larger areas of myocardial involvement compared
with healthy and hypertensive control subjects
(median 22% vs. 1% and 2% LV myocardium, respec-
tively; both p < 0.05). On follow-up, the area of T1
abnormality had regressed signiﬁcantly on paired
analysis (median 19% to 12%; p < 0.02), but not back
to normal as compared with healthy control subjects
(median 1%; p < 0.05).
Patients with previously diagnosed, surgically
treated pheochromocytoma without evidence of
active disease also demonstrated signiﬁcantly larger
FIGURE 2 Myocardial Strain Parameters
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Subclinical systolic (A) and diastolic (B) dysfunction in pheochromocytoma was detected
by impaired myocardial strain parameters on tagged CMR. Bar graphs indicate mean strain
parameters; error bars indicate SD. *p < 0.05. Dx ¼ diagnosis; HTN ¼ hypertensive;
Pheo ¼ pheochromocytoma; Pre-op ¼ pre-operatively; Post-op ¼ post-operatively.
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Downloaded From: http://content.onlinejacc.org/ on 05/17/2016areas of myocardial involvement detected by native
T1 mapping compared with healthy and hypertensive
control subjects (median 12% vs. 2% and 2%, respec-
tively; both p < 0.05). This is comparable to that seen
in newly diagnosed patients post-operatively in
follow-up (also median 12%).
DISCUSSION
This is the ﬁrst systematic study using advanced CMR
imaging, including mapping techniques, to charac-
terize the cardiac phenotype in stable patients with
pheochromocytoma (Central Illustration). We have
shown that: 1) cardiac involvement is common in this
cohort, including global LV dysfunction, impaired
systolic and diastolic strain parameters, myocarditis,
pericardial effusion, and markers for focal and diffuse
ﬁbrosis; 2) although some abnormalities, such as
global LV dysfunction and myocardial edema, are
reversible, there are subclinical abnormalities that
persisted over time, even after curative resection of
the pheochromocytoma without biochemical evi-
dence of ongoing disease, including subclinical sys-
tolic and diastolic dysfunction and markers for focal
and diffuse ﬁbrosis; and 3) compared with hyperten-
sive control subjects, the cardiac changes are beyond
and distinct from those observed in hypertensive
heart disease alone, and importantly, LVH is not a
typical feature in pheochromocytoma. These ﬁndings
support the direct role of catecholamine toxicity to
the heart, which may lead to a form of catecholamine-
induced myocarditis that produces some subtle but
long-lasting myocardial alterations.
FINDINGS IN CATECHOLAMINE MYOCARDITIS. Cat-
echolamines have been shown to cause direct
myocardial toxicity, with pathological changes such
as contraction band necrosis via mechanisms such
as alpha-receptor–mediated vasoconstriction and
oxygen-derived free radical injury, leading to myo-
cyte membrane damage and death (8,14,22,23). Van
Vliet et al. (22) examined the hearts of 26 patients
who died with a pheochromocytoma compared with
256 control subjects, taking into account sex, age,
degree of coronary atherosclerosis, hypertension,
and types of myocardial disease (22). Pathological
cardiac ﬁndings revealed disseminated focal
myocardial lesions in 58% of the patients (similar to
our ﬁndings of nonischemic focal ﬁbrosis in 59% of
newly diagnosed patients), characterized by focal
degeneration and necrosis of myocardial ﬁbers, and
foci of inﬂammatory cells and diffuse myocardial
edema, designated as “active catecholamine
myocarditis.” We detected increased ﬁbrous tissue in
TABLE 2 Paired Comparison of CMR Characteristics Pre- and Post-Surgery
Patients With
New Dx of
Pheochromocytoma
Pre-Operation
Patients With
New Dx of
Pheochromocytoma
Post-Operation p Value
LV ejection fraction, % 60  9 63  5 <0.03*
LV end-diastolic volume
indexed to BSA, ml/m2
76  16 71  13 <0.02*
LV end-systolic volume
indexed to BSA, ml/m2
32  13 27  8 <0.02*
LV mass indexed to BSA, g/m2 58  13 52  8 0.02*
Peak systolic circumferential strain (s1) 15.1  3.0 16.2  3.3 NS
Peak diastolic
circumferential strain rate, s1
72.3  24.5 65.1  18.4 NS
Mean myocardial T1, ms 973  26 964  24 NS
Myocardial injury by T1 $990 ms, % 19 (9–37) 12 (4–19) <0.02*
LV myocardium with LGE >2 SD, % 5 (3–7) 5 (2–12) NS
Values are mean  SD or median (interquartile range). *Statistically signiﬁcant on paired analysis; follow-up CMR
was performed at a mean of 12  5 months.
Abbreviations as in Table 1.
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Downloathe same distribution as the inﬂammatory lesions
that appeared to have replaced myocardial ﬁbers
around small vessels. In patients without active
catecholamine myocarditis, 2 demonstrated marked
myocardial ﬁbrosis, similar in appearance and distri-
bution to the ﬁbrosis of those with active myocarditis
without severe coronary atherosclerosis to explain
the ﬁndings, and likely represented the healed stage
of the acute catecholamine myocarditis. Importantly,
patients who had nonfunctioning pheochromocy-
tomas did not demonstrate these lesions, and only 7%
in the control group demonstrated histological evi-
dence of myocarditis, of which none had the same
histologic characteristics of patients with
pheochromocytoma.
These ﬁndings were similar to those of earlier
studies in experimental animal models and patients
treated with L-norepinephrine and in patients with
pheochromocytoma, described as both acute necrotic
and inﬂammatory lesions, as well as chronic ﬁbrosing
lesions (23–26). No evidence of eccentric or dispro-
portional septal hypertrophy was observed. Thus,
catecholamines in pheochromocytoma exert a direct
cardiotoxic effect; this is a distinct entity whose
footprint may be observed histologically in various
stages of this pathological process, including degen-
erative changes in muscle ﬁbers, foci of necrosis,
acute inﬂammation, chronic interstitial inﬂammatory
exudation, and reparative ﬁbrosis. On CMR, these
may be observed noninvasively as myocardial ne-
crosis, edema, and focal and diffuse ﬁbrosis that may
lead to short- or long-term functional changes.
Indeed, many of these morpho-functional alter-
ations were demonstrated by this CMR study. Acute
myocarditis may be detected using highly sensitive
myocardial T1 mapping (19). In patients with newly
diagnosed pheochromocytoma, native T1 mapping
detected signiﬁcant areas of myocarditis compared
with control subjects; this diminished post-
operatively over time along with LV mass regres-
sion, supporting a degree of acute myocarditis that is
reversible post-surgical treatment, but T1 did not
completely normalize. Similarly, patients with previ-
ous surgically treated pheochromocytoma, without
clinical evidence of active disease, also demonstrated
myocardial T1 abnormalities, albeit to a lesser degree
than the newly diagnosed patients. It should be noted
that diffuse and focal myocardial ﬁbrosis may elevate
native myocardial T1 (27,28). Thus, it is plausible that
in some of these patients, after acute myocarditis
resolution, T1 mapping may detect reparative changes
that have begun, including development of focal and
diffuse myocardial ﬁbrosis (6). The high incidence
(59%) of focal myocardial ﬁbrosis on LGE imagingded From: http://content.onlinejacc.org/ on 05/17/2016seen in newly diagnosed patients supports the notion
that the T1 changes seen at pre-operative baseline
may represent a combination of acute and chronic
myocardial changes, depending on the age and
functional status of a patient’s pheochromocytoma.
Although we do not have veriﬁcation via histopath-
ological correlation, this hypothesis is an attractive
explanation consistent with both human and animal
histopathological studies and the natural history of
this condition (1,4,6,8,22,24,26).
Further, these myocardial abnormalities appear to
be distinct from those of hypertensive heart disease
or pressure overload alone. First, the catecholamine-
induced pattern of hypertension is highly variable,
often paroxysmal either on a background of sustained
hypertension or normotension in between periods of
hypertension (6). Second, blood pressure patterns
also appear to be distinct from essential hypertension
(10), with greater daytime variability and lack of a
nocturnal dip (29,30), implying different mechanisms
of hypertension, making it difﬁcult to ﬁnd matching
control subjects (1). Perhaps most convincing:
although some studies have described an association
between plasma norepinephrine levels and LVH
(22,31,32), only a subset (w25% to 40% of patients)
with pheochromocytoma demonstrated echocardio-
graphic evidence of LVH in other studies (1,6,33–35).
Our study demonstrated a similar lack of LVH in these
patients, and we have carefully chosen hypertensive
control subjects without severe LVH to more closely
match the morphological LV phenotype of patients
with pheochromocytoma; these patients demon-
strated cardiac ﬁndings that are distinct from and
FIGURE 3 Catecholamine Myocarditis and Left Ventricular Involvement
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To compare patients with pheochromocytoma with healthy and hypertensive control
subjects, myocardial involvement was detected using the threshold of T1 >990 ms
for myocarditis. Bar graphs indicate the median extent of myocardial involvement per
subject; error bars indicate interquartile range. All comparisons are statistically
signiﬁcant (p < 0.05) except as marked. NS ¼ not signiﬁcant; other abbreviations as
in Figure 2.
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Downloaded From: http://cobeyond those seen in patients with essential hyper-
tension, supporting a direct role of catecholamine
myocardial toxicity (10).
Exposure to catecholamines may result in myocar-
dial alterations that lead to overt or subclinical
myocardial dysfunction, which may or may not
reverse over time. Per reports, myocardial contractile
dysfunction and catecholamine-induced cardiomy-
opathies are reversible with pharmacological and
surgical treatment of the pheochromocytoma
(1,4,7,36). Although our ﬁndings are generally
consistent with the reversibility of overt LV dysfunc-
tion measured via global indexes such as LVEF, we
uncovered subclinical systolic and diastolic dysfunc-
tion that persisted over time, despite surgical cure of
the pheochromocytoma and with no clinical evidencentent.onlinejacc.org/ on 05/17/2016of ongoing catecholamine activity. As discussed, this
is accompanied by ﬁndings of focal ﬁbrosis on LGE
imaging and the failure of myocardial T1 values to
completely normalize in follow-up, possibly reﬂecting
development of some diffuse myocardial ﬁbrosis
detectable using T1 mapping (27). This paralleled a
recent study by Galetta et al. (37) that examined
myocardial wall texture in patients with pheochro-
mocytoma using ultrasonic tissue characterization of
the myocardium, expressed as tissue integrated
backscatter. Their results demonstrated adverse
myocardial remodeling characterized by an increase
in the overall myocardial backscatter level compared
with hypertensive and normotensive control subjects;
this is consistent with increased myocardial collagen
content and ﬁbrosis, which determines early diastolic
dysfunction (37). The ﬁndings from this and our study
suggest that the myocardial injury sustained during
the course of catecholamine exposure may be
accompanied by reparative processes such as focal
and diffuse ﬁbrosis or other ultrastructural changes
post-catecholamine myocarditis. Furthermore, cate-
cholamine toxicity is not completely benign and
may not be quickly reversible, leaving long-lasting
changes in the form of subtle systolic and diastolic
dysfunction.
STUDY LIMITATIONS. Due to the rarity of the condi-
tion, this study has a relatively small sample size,
although it is the largest study to date using CMR as a
phenotypic tool. Given that the changes are subclin-
ical, larger studies are needed to conﬁrm these ﬁnd-
ings and determine their long-term clinical
signiﬁcance. We recruited patients with pheochro-
mocytoma mostly from the outpatient setting, so se-
lection bias existed, and this study’s ﬁndings
characterize a more stable cohort without more
severe cardiovascular complications (6). Similar to
other studies of patients with pheochromocytoma, it
is difﬁcult to ﬁnd an appropriate hypertensive control
group (4,10) to match the variable patterns of hyper-
tension in pheochromocytoma that seem to be
distinct from those of essential hypertension and to
clearly delineate which ﬁndings are attributable to
hypertension alone, are attributable to catecholamine
toxicity, or may be synergistic. Endomyocardial bi-
opsy was not indicated in these patients, and as such,
direct histopathological correlation to the imaging
ﬁndings is not available.
CONCLUSIONS
Cardiac involvement was frequent and often persis-
tent in pheochromocytoma, including myocarditis,
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Beyond the
effects of hypertension, pheochromocytoma is associated with
catecholamine-induced cardiac toxicity. This is characterized by
myocardial inﬂammation, myocyte necrosis, and ﬁbrosis that can
lead to systolic and diastolic dysfunction.
TRANSLATIONAL OUTLOOK: Further research is needed to
identify speciﬁc CMR imaging ﬁndings associated with long-term
prognosis in patients with pheochromocytoma.
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Downloaglobal LV dysfunction, subclinical systolic and dia-
stolic dysfunction, and focal and diffuse ﬁbrosis.
These changes extended beyond the effects of
hypertensive heart disease alone, supporting a direct
role of catecholamine toxicity that may result in
subtle but long-lasting myocardial alterations. Larger
and longer-term studies may determine whether
early detection of catecholamine-induced cardiac
changes may be useful for risk stratiﬁcation, pre-
dicting clinical cardiovascular events, or early treat-
ment to minimize long-term myocardial damage in
pheochromocytoma.
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